Abstract | BACKGROUND: METHODS: We developed an observational prospective study with a total of 125 subjects: 40 patients with acute CAD, 40 patients with chronic CAD and 45 control volunteers, in whom serum levels of Cyps (CypA, CypB, CypC and CypD), interleukins and metalloproteinases were measured. RESULTS: CypA levels increased significantly in CAD patients compared with control subjects, but no differences were noted between acute CAD (7.80 ± 1.30 ng/mL) and chronic CAD (5.52 ± 0.76 ng/mL) patients (P = 0.13). No differences in CypB and CypD levels were showed between CAD patients and controls and between acute CAD and chronic CAD patients. In relation with CypC, the levels in CAD patients were significantly higher compared to controls (32.42 ± 3.71 pg/mL vs. 9.38 ± 1.51 pg/mL, P < 0.001), but no differences between acute and chronic CAD groups were obtained (P = 0.62). We analyzed the CypC > 17.5 pg/mL cut-off point, and it was significantly associated with older age, hypertension, dyslipidemia and more extensive CAD in acute and chronic CAD groups. CONCLUSIONS: CypA and CypC levels are increased in CAD patients. High CypC serum levels could be a novel biomarker in CAD patients correlating with a more severe disease.
|
Authors | Jeremias Bayon, Amparo Alfonso, Sandra Gegunde, Eva Alonso, Rebeca Alvarino, Melisa Santas-Alvarez, Ana Testa-Fernandez, Ramon Rios-Vazquez, Luis Botana, Carlos Gonzalez-Juanatey |
Journal | Cardiology research
(Cardiol Res)
Vol. 11
Issue 5
Pg. 319-327
(Oct 2020)
ISSN: 1923-2829 [Print] Canada |
PMID | 32849967
(Publication Type: Journal Article)
|
Copyright | Copyright 2020, Bayon et al. |